Tickers featured: AKSY, ALT, AMEV, ARIA, ASCO, AVII, AZN, BGEN, BMRN, CGPI, CPHD, CYPB
, DNA, DYAX, ENCY, GENZ, GERN, GNLB, GNTA, INKP, ISIS, MEDI, MLNM, NVS, RGEN, RITA, SUPG, TNOX, UTHR.
Cypress is moving onto the NMS from the Nasdaq Small Cap Market while retaining the same ticker symbol, CYPB
CYPB is currently awaiting FDA review of its completed PMA submission for the Prosorba(R) column for Rheumatoid Arthritis ("RA"), and recently announced that the FDA will review this submission at an October 29, 1998 Advisory Panel meeting.
Valuation and Timing: We believe CYPB shares offer very good value at current levels based on the potential for Prosorba(R) for RA alone; likely milestones in 1998 should positively affect institutional interest, Wall Street sponsorship and, ultimately, the share price.
Prosorba(R) for RA: Following what we believe will be a positive recommendation from the FDA Advisory Committee meeting October 29, we believe CYPB will receive FDA approval for Prosorba(R) for RA by the end of 1998.
Tickers featured: AMGN, AVE, CYPB
, DNA, GNLB, GNTA, ISIS, MOGN, REGN, RGEN, SUPG, XOMA.
Tickers featured: CGPI, CYPB
, DRRX, ENDP, FRX, NGSX.
Tickers featured: ABT, ACOR, AMGN, AUXL, AZN, BIIB, CELG, CYPB
, DNDN, ELN, FRX, GENZ, GILD, HGSI, JNJ, LLY, MYGN, PFE, REGN, RHHBY, SNY, UTHR, VRTX, XNPT.